Rejection of the second allogeneic graft in a patient with severe aplastic anemia reversed by antilymphocyte globulin and donor lymphocyte infusions

P Ljungman, M Lawler, B Lönnqvist, O Ringdén, A Shanwell, Mark Lawler

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Rejection after allogeneic BMT for aplastic anemia is a complication with a high risk of mortality. We describe a patient who, following a second episode of rejection after a second BMT entered a third durable remission subsequent to treatment with ALG, donor lymphocyte infusions, GM-CSF, and erythropoietin. Therapy was well tolerated. At 5 years after rejection treatment, his hematopoiesis is of complete donor origin as determined by analyses of short tandem repeats. Thus, donor lymphocyte infusions can be considered as a therapy option for marrow rejection after allogeneic BMT for aplastic anemia.

Original languageEnglish
Pages (from-to)1179-81
Number of pages3
JournalBone Marrow Transplantation
Volume18
Issue number6
Publication statusPublished - Dec 1996

Keywords

  • Adult
  • Anemia, Aplastic
  • Antilymphocyte Serum
  • Bone Marrow Transplantation
  • Cyclosporine
  • Erythropoietin
  • Graft Rejection
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Humans
  • Immunosuppression
  • Immunosuppressive Agents
  • Lymphocyte Transfusion
  • Male
  • Microsatellite Repeats
  • Polymerase Chain Reaction
  • Remission Induction
  • Transplantation, Homologous

Fingerprint Dive into the research topics of 'Rejection of the second allogeneic graft in a patient with severe aplastic anemia reversed by antilymphocyte globulin and donor lymphocyte infusions'. Together they form a unique fingerprint.

  • Cite this